Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and children over the age of 6.
Unipharm’s generic Atomoxetine Oral Solution has been manufactured and marketed in Israel since 2021. In recent years, Unipharm’s Atomoxetine Oral Solution has raised interest in several EU countries.
